2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

1563 Clinical and molecular characteristics of dic(9;20)-positive acute lymphoblastic leukemia: An international cohort study

Aavani Biju Sindhu, Zeljko Antic, MD, PhD2, Martin Zimmermann, PhD3, Judith Mary Boer, PhD4, Hester A. de Groot-Kruseman, PhD5, Monique L. Den Boer, PhD6, Rob Pieters, MD, PhD, MSc7, Karin Nebral8, Andishe Attarbaschi9, Sabine Strehl, PhD10, Oskar A Haas, MD11, Lucie Šrámková, MD12, Marketa Zaliova, MD, PhD13, Iveta Janotová14, Jan Zuna, MD, PhD15, Richard Tilman Hauch16, Udo Zur Stadt, PhD17, Gabriele Escherich, MD, PhD18, Agata Pastorczak, MD, PhD19, Monika lejman, MD, PhD, Prof. UM20, Grazia Fazio, PhD21, Fondazione Andrea22, Barbara Buldini, MD, PhD23, Valentino Conter24, Giovanni Cazzaniga, MD, PhD25, Kean Hui Chiew26, Allen Eng Juh Yeoh, MD27, Hany Ariffin28, Vasilios Zachariadis29, Ann Nordgren, MD, PhD30, Mats Heyman, MD, PhD31, Arja Harila32, Olli Lohi, MD, PhD33, Ulrika Norén-Nyström, MD, PhD34, Kjeld Schmiegelow, Professor35, Claudia Althaus36, Renate Siegenthaler37, Nastassja Scheidegger, MD38, jean Pierre Bourquin, MD, PhD39, Hsi-Che Liu, MD40, Mary Shago, PhD41, Hiroto Inaba, MD. PHD42, Charles G. Mullighan, MBBS (Hons), MSc, MD43, Meenakshi Devidas, PhD44, David T. Teachey, MD45, Sarah Elitzur46, Anthony Moorman, PhD47, Martin Schrappe, MD48, Gunnar Cario, MD49, Anke K. Bergmann50
1 Medizinische Hochschule Hannover, Hannover, Lower saxony, Germany, University Hospital Würzburg, Würzburg, Bavaria, Germany
2 University Hospital Würzburg, Würzburg, Bavaria, Germany
3 Medizinische Hochschule Hannover, Hannover, Lower Saxony, Germany
4 Prinses Máxima Centrum Voor Kinderoncologie, Utrecht, Netherlands
5 Prinses Máxima Centrum Voor Kinderoncologie, Utrecht, Netherlands
6 Prinses Máxima Centrum Voor Kinderoncologie, Utrecht, Netherlands
7 Prinses Máxima Centrum Voor Kinderoncologie, Utrecht, Netherlands
8 Labdia Labordiagnostik, Wien, Austria, St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria, Vienna, Austria
9 St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria, Vienna, Austria, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria, Vienna, Austria
10 St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria, Vienna, Austria
11 Labdia Labordiagnostik, Wien, Austria, St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria, Vienna, Austria, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria, Vienna, Austria
12 Charles University and University Hospital Motol, Prague, Czech Republic
13 Charles University and University Hospital Motol, Prague, Czech Republic
14 Charles University and University Hospital Motol, Prague, Czech Republic
15 Charles University and University Hospital Motol, Prague, Czech Republic
16 University Medical Center Hamburg-Eppendorf, Germany, Hamburg, Germany
17 University Medical Center Hamburg-Eppendorf, Germany, Hamburg, Germany
18 University Medical Center Hamburg-Eppendorf, Germany, Hamburg, Germany
19 Medical University of Lódz, Lódz, Poland
20 Medical University of Lublin, Lublin, Poland, University Children's Hospital in Lublin, Lublin, Poland
21 Centro Tettamanti, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
22 School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
23 Fondazione Istituto Ricerca Pediatrica (IRP), Padua, Italy, University of Padua, Padova, Italy
24 Centro Tettamanti, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
25 Centro Tettamanti, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
26 National University Hospital, Singapore, Singapore
27 National University Hospital, Singapore, Singapore
28 Universiti Malaya Kuala Lumpur, Kuala Lumpur, Malaysia
29 Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
30 Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
31 Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
32 Uppsala University, Uppsala, Sweden
33 Tampere University Hospital, Finland, Tampere, Finland
34 Umeå University, Umeå, Sweden
35 Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
36 University Children's Hospital Zurich, Switzerland, Zurich, Switzerland
37 University Children's Hospital Zurich, Switzerland, Zurich, Switzerland
38 University Children's Hospital Zurich, Switzerland, Zurich, Switzerland
39 University Children's Hospital Zurich, Switzerland, Zurich, Switzerland
40 Mackay Children's Hospital and Mackay Medical University, Taipei, Taiwan
41 Hospital for Sick Children, Toronto, Canada
42 St.Jude Children's research Hospital, Memphis, Tennessee, United States
43 St.Jude Children's research Hospital, Memphis, Tennessee, United States
44 St.Jude Children's research Hospital, Memphis, Tennessee, United States
45 The Children Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
46 Schneider Children's Medical Center and Gray Faculty of Medical and Health Sciences, Tel Aviv, Israel, St.Jude Children's research Hospital, Memphis, Tennessee, United States
47 Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
48 Christian-Albrechts University, Kiel, Germany, University Medical Center Schleswig-Holstein, Kiel, Germany
49 University Medical Center Schleswig-Holstein, Kiel, Germany
50 Medizinische Hochschule Hannover, Hannover, Lower saxony, Germany, University Hospital Würzburg, Würzburg, Bavaria, Germany

Background:

Dicentric chromosome dic(9;20)(p11-13;q11) is a recurrent cytogenetic abnormality in ~2% of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cases. Its clinical and genomic characteristics and prognostic determinants remain poorly defined, largely because previous studies have included small patient cohorts. Here, we conducted an international collaborative study to comprehensively characterize the clinical and genomic features and identify prognostic markers of dic(9;20)-positive BCP-ALL.

Methods:

We identified 489 children, adolescents, and young adults with dic(9;20)-positive BCP-ALL diagnosed between 1989 and 2024 across 13 international study groups. Survival analyses were performed in 431 patients; molecular profiling was available for 276 (MLPA n=75, DNA array n=126, RNA-seq n=186). Overall survival (OS) and event-free survival (EFS) were estimated via Kaplan-Meier; cumulative incidence of relapse (CIR) was estimated adjusting for competing risks. Multivariable Cox models (adjusted for NCI-risk and end-of-induction MRD) was used to identifiy independent predictors of EFS and relapse.

Results:

The cohort comprised 211 (43.1%) male and 278 (56.9%) female patients, with a median age at diagnosis of 3 years (range, 0–30y). The majority of patients were aged 1–5 years (401, 82.0%), followed by 6–9 years (40, 8.2%), ≥10 years (44, 9.0%) and infants (4, 0.8%). Of 488 patients with evaluable clinical data, 314 (64.3%) were classified in the standard risk and 174 (35.7%) in the high-risk group, according to NCI criteria. The 5-year CIR was 18.8%, while 5-year OS and EFS were 93.5% and 78.3%, respectively. Among the 74 patients who relapsed, the median time from diagnosis to relapse was 2.37 years (95% CI, 2.13–2.74), and relapse predominantly involved the bone marrow (59.5%), CNS (18.9%), or combined bone marrow/CNS sites (10.8%). Compared to SR patients, HR patients had inferior OS (89.0% vs 95.8%, P=0.001), EFS (69.8% vs 82.7%, P=0.002), and higher CIR (24.6% vs 15.9%, P=0.021).

The genomic landscape was characterised by frequent deletions involving CDKN2A (97.8%), CDKN2B (96.1%) and PAX5 (95.0%), as well as recurrent deletions affecting IKZF1 (37.7%), RB1 (17.7%) and ERG (9.6%) genes. Deletions of PAR1, comprising P2RY8::CRLF2 and other CRLF2 deletions were identified in 22.1% of evaluable cases. Deletions of IKZF1 were associated with inferior EFS (59.2% vs 82.5%, P=0.0026) and increased CIR (31.9% vs 16.6%, P=0.0325). Similarly, cases with PAR1 deletions had inferior 5-year EFS (46.9% vs 79.3%, P=0.0031) and a higher, albeit not statistically significant, CIR (34.1% vs 17.6%, P=0.0518). Furthermore, within this group, patients with a documented P2RY8::CRLF2 fusion showed particularly poor outcomes, with 5-year EFS of 46.9% versus 75.5% (P=0.065) and CIR of 53.1% versus 17.8% (P=0.0066). Among recurrent gene rearrangements, PAX5::NOL4L was the most frequent fusion (42/186, 22.6%), followed by P2RY8::CRLF2 (18/186, 9.7%). Furthermore, PAX5::NOL4L showed non-significant trends toward inferior 5-year EFS (58.5% vs 76.9%, P=0.133) and higher CIR (35.1% vs 17.2%, P=0.090). However, none of the evaluated genomic alterations showed significant effects on OS.

In multivariable Cox analyses adjusted for NCI risk group and end-of-induction MRD, IKZF1 deletions remained an independent predictor of inferior EFS (HR 2.25, 95% CI 1.19-4.26; P=0.013). Deletions of PAR1 region, resulting in P2RY8::CRLF2 fusions, independently predicted inferior EFS (HR 3.42, 95% CI 1.34-8.76; P=0.010) and relapse (HR 4.25, 95% CI 1.35-13.38; P=0.014). In contrast, cases with CRLF2 deletions, but without a documented P2RY8::CRLF2 fusions showed a non-significant trend toward inferior EFS (HR 2.77, 95% CI 0.92–8.33; P=0.070).

Conclusions:

This study represents the largest international study of children, adolescents, and young adults with dic(9;20)-positive BCP-ALL to date, providing a comprehensive overview of the demographic, clinical, and molecular characteristics of this subtype. Our findings confirm the adverse prognostic relevance of IKZF1 deletions and P2RY8::CRLF2 fusions within dic(9;20)-positive BCP-ALL and support the applicability of contemporary molecular risk-stratification approaches to this rare cytogenetic subgroup. Despite relapse remaining the principal cause of treatment failure, the excellent overall survival suggests that many relapsed patients could be successfully salvaged.

Aavani Biju Sindhu: No relevant conflicts of interest to declare.